Efficacy and safety of rituximab in a multicentre Brazilian cohort of patients with generalized myasthenia gravis
Background: Myasthenia gravis (MG) is an autoimmune neuromuscular disorder mediated by antibodies targeting components of the postsynaptic membrane at the neuromuscular junction. Up to 15% of patients develop refractory disease despite standard immunotherapies. Current guidelines recommend rituximab as a first-line opt...